That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Ricky Chiu Yin-to, founder of Hong Kong biotech firm Phase Scientific, aims to develop an easier method for cervical cancer screening using urine-based HPV tests. During the pandemic, his company became known for its Indicaid rapid antigen test, which received US emergency-use authorization in July 2021 and was used extensively both locally and internationally. The company's workforce grew from 20-30 employees to a peak of around 400 during the pandemic, with monthly production reaching up to 30 million tests. Chiu plans to use the resources gained during this period to advance research on early cancer detection methods.
Written locally by qwen2.5:14b on 2026-10-11,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
Ricky Chiu Yin-to, founder of Phase Scientific, is developing a urine-based HPV test to make cervical cancer screening more accessible. This builds on the company's success during the pandemic with its Indicaid rapid antigen test, which received US emergency-use authorization in July 2021 and was widely used in Hong Kong and internationally.
During the peak of the pandemic, Phase Scientific grew from employing around 20 to 30 people to having a workforce of up to 400. The company produced as many as 30 million rapid tests per month during this period. Chiu plans to use the funds and technological advancements gained during the pandemic to further develop long-term research initiatives, such as the cervical cancer test.
Written for “Hong Kong Biotech Breakthrough” on 2026-10-11,
grounded in this article and the 0 other(s) covering the same event.
biotech firm eyes cervical cancer test breakthrough
asserted
firm → eye → breakthrough
Phase Scientific founder Ricky Chiu is drawing on his firm’s pandemic experience to advance early detection methods through urine-based HPV testing
Hong Kong biotech entrepreneur Ricky Chiu Yin-to is seeking to make cervical cancer screening easier through urine-based HPV testing, using sample-concentration technology developed by his company.
asserted
screening → draw → company
His company, Phase Scientific, made its name during the Covid-19 pandemic through its rapid antigen test, Indicaid.
asserted
company → make → test
The product received US emergency-use authorisation in July 2021, was used in Hong Kong community testing and sold in more than 30 countries.
asserted
product → receive → countries
At the start of the pandemic, the firm employed 20 to 30 people.
asserted
firm → employ → people
Its headcount later peaked at around 400, while monthly production reached as many as 30 million rapid tests.
asserted
production → peak → tests
Chiu said business during the pandemic gave the company the funds, manufacturing experience, team and technology to pursue longer-term research after demand for rapid testing subsided.
asserted
demand → say → testing
The Aporia
